Vor bio reports fourth quarter and full year 2021 financial results and provides company update

Cambridge, mass., march 14, 2022 (globe newswire) -- vor bio (nasdaq: vor), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period and full year ended december 31, 2021, and provided a business update.
VOR Ratings Summary
VOR Quant Ranking